azomycin has been researched along with Tuberculosis, Drug-Resistant in 190 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.05) | 29.6817 |
| 2010's | 121 (63.68) | 24.3611 |
| 2020's | 67 (35.26) | 2.80 |
| Authors | Studies |
|---|---|
| Campino, S; Clark, TG; Gomes, P; Gómez-González, PJ; Hibberd, ML; Napier, G; Perdigao, J; Phelan, JE; Portugal, I; Puyen, ZM; Santos-Lazaro, D; Viveiros, M | 1 |
| Bastos, MM; Bernardino, AMR; Boechat, N; Castelo-Branco, FS; Cruz, YODD; da Costa, PHA; de Oliveira, AP; Faria, JV; Junior, PAS; Lourenço, MCS; Murta, SMF; Passos, FPZ | 1 |
| Hafkin, J; Karlsson, MO; Mallikaarjun, S; Sasaki, T; Svensson, EM; Wang, X; Wang, Y | 1 |
| Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A | 1 |
| Howell, P; Mvuna, N; Olugbosi, M; Upton, C | 1 |
| Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W | 1 |
| Adenov, M; Adnan, S; Ahmed, S; Bastard, M; Coutisson, S; Danielyan, N; Franke, MF; Hewison, C; Huerga, H; Islam, S; Janmohamed, A; Kamene Kimenye, M; Karakozian, H; Khan, P; Khan, U; Kholikulov, B; Kirakosyan, O; Krisnanda, A; Kumsa, A; Lachenal, N; Leblanc, G; Lecca, L; Mamsa, S; Melikyan, N; Mitnick, CD; Nkuebe, M; Osso, E; Padayachee, S; Rich, ML; Seung, KJ; Thit, P; Varaine, F | 1 |
| Bax, HI; De Steenwinkel, JEM; Lenaerts, A; Mudde, SE; Upton, AM | 1 |
| Antony, S; Bodhanwala, M; Jaiswal, A; Parmar, M; Sachdeva, KS; Salve, J; Shah, D; Shah, I; Tipre, P | 1 |
| Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L | 1 |
| Akkerman, O; Al-Abri, S; Alffenaar, JW; Amini, S; Arabpour, E; Centis, R; Chakaya, J; D'Ambrosio, L; Dalcolmo, MP; Denholm, JT; Khalili, F; Kurhasani, X; Migliori, GB; Muňoz-Torrico, M; Nasiri, MJ; Pontali, E; Saderi, L; Schaaf, HS; Seaworth, B; Silva, DR; Sotgiu, G; Tiberi, S; van den Boom, M; Zangiabadian, M; Zumla, A | 1 |
| De Leon, A; Frias, M; Garcia-Prats, AJ; Gler, MT; Hafkin, J; Hesseling, AC; Malikaarjun, S; Schaaf, HS; van der Laan, L | 1 |
| Betteridge, M; Boekelheide, K; Everitt, D; Nedelman, J; Olugbosi, M; Smith, E; Spigelman, M; Sun, E | 1 |
| De Los Rios, J; Diacon, AH; Dooley, KE; Karlsson, MO; Maartens, G; Shenje, J; Svensson, EM; Tanneau, L; Upton, CM; Wiesner, L | 1 |
| Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y | 1 |
| Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R | 1 |
| Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P | 1 |
| Ashkin, D; Goswami, ND; Haley, CA | 1 |
| Bekele, F; Fekadu, G; Fetensa, G; Tolossa, T; Turi, E | 1 |
| Apolisi, I; Beko, B; Cengani, L; Cox, H; Daniels, J; Fatshe, S; Furin, J; Gumede, N; Joseph, K; Mathee, S; Maugans, C; Memani, B; Reuter, A; Tyeku, N | 1 |
| Andersen, ÅB; Dahl, VN; Guglielmetti, L; Holmgaard, FB; Lillebaek, T; Wejse, C | 1 |
| Lyons, MA | 2 |
| Groenheit, R; Grönfors Seeth, C; Karlsson Lindsjö, O; Mansjö, M; Werngren, J | 1 |
| Bahr, M; Brosnan, MK; Chen, X; Dannals, RF; De Jesus, P; Erice, C; Flavahan, K; Holt, DP; Jain, SK; Kim, J; Lodge, MA; Mota, F; Ordonez, AA; Peloquin, CA; Ruiz-Bedoya, CA; Tucker, EW | 1 |
| Aston, S; Davies, GR | 1 |
| Aarnoutse, R; Andres, S; Choong, E; Decosterd, LA; Dreyer, V; John, A; Kalsdorf, B; Koehler, N; König, C; Krieger, D; Kuhns, M; Lange, C; Maurer, FP; Merker, M; Niemann, S; Peloquin, CA; Sanchez Carballo, PM; Schaub, D; Schön, T; Schönfeld, N; Verougstraete, N; Verstraete, AG; Werngren, J; Wicha, SG; Zur Wiesch, PA | 1 |
| Betoudji, F; Converse, PJ; Fotouhi, N; Lee, J; Li, SY; Mdluli, K; Nuermberger, EL; Upton, A | 1 |
| Millard, J; Nimmo, C; O'Donnell, M; Rimmer, S | 1 |
| Bi, J; Li, L; Mi, K; Zhou, X; Zhu, H; Zhuang, Z | 1 |
| Alghamdi, WA; Alshaer, MH; Avaliani, Z; Barbakadze, K; Benkeser, D; Blumberg, HM; Jin, Y; Kempker, RR; Kipiani, M; Maranchick, NF; Mikiashvili, L; Peloquin, CA | 1 |
| Alffenaar, JC; Anthony, RM; Nguyen, QH; Nguyen, TNT; Nguyen, TVA; Vu, DH | 1 |
| Ahrenstorf, G; Friesen, I; Joean, O; Kuhns, M; Picksak, G; Ringshausen, FC; Trauth, J; Welte, T | 1 |
| Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V | 1 |
| Atwood, S; Bastard, M; Franke, MF; Hewison, C; Huerga, H; Khan, AJ; Khan, PY; Khan, U; Mitnick, CD; Rich, M; Seung, KJ; Varaine, F | 1 |
| Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM | 1 |
| Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S | 1 |
| Burki, T | 1 |
| Mushtaq, A | 1 |
| Dheda, K; Esmail, A; Limberis, J; Olayanju, O | 1 |
| Ahmed, S; Aiylchiev, S; Alam, M; Bastard, M; Docteur, W; Franke, MF; Gottlieb, G; Hewison, C; Huerga, H; Islam, S; Khachatryan, N; Khan, P; Khan, U; Kotrikadze, T; Kumsa, A; Lecca, L; Melikyan, N; Mitnick, CD; Naing, YY; Oyewusi, L; Putri, FA; Rich, M; Seung, KJ; Tassew, YM; Wanjala, S; Yedilbayev, A | 1 |
| Avaliani, Z; Bablishvili, N; Barbakadze, K; Benkeser, D; Blumberg, HM; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA; Zhao, Y | 1 |
| Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E | 1 |
| Aher, RB; Sarkar, D | 1 |
| Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH | 1 |
| Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H | 1 |
| Cooper, CB; Denny, WA; Ding, CZ; Ding, J; He, S; Lu, Y; Lynch, AS; Ma, Z; Upton, AM; Wan, D; Wang, X; Yuan, Y; Zhang, Q; Zhuang, Z | 1 |
| Alffenaar, JC; Anthony, RM; Bañuls, AL; Cao, TTH; Nguyen, NV; Nguyen, TVA; Nguyen, VAT; Vu, DH | 1 |
| Jeon, D; Jo, KW; Kang, H; Lee, HH; Shim, TS; Yim, JJ | 1 |
| Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R | 1 |
| Ader, F; Chiesi, S; Dominguez, J; Eimer, J; Guglielmetti, L; Masini, T; Robert, J; Varaine, F; Veziris, N | 1 |
| Beko, B; Cox, H; Daniels, J; De Avezedo, V; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Makhanda, G; Mohr-Holland, E; Reuter, A; Trivino Duran, L | 1 |
| Aono, A; Kato, S; Mitarai, S; Ohta, K; Okumura, M; Takaki, A; Yoshiyama, T | 1 |
| Mathema, B; O'Donnell, M | 1 |
| Avihingsanon, A; Borrell, S; Böttger, EC; Collantes, J; Egger, M; Fenner, L; Gagneux, S; Hömke, R; Keller, PM; Loiseau, C; Reichmuth, ML; Reinhard, M; Sander, P; Wilkinson, RJ; Yotebieng, M; Zürcher, K | 1 |
| Alikhanova, N; Barbova, A; Battaglia, S; Cabibbe, AM; Cirillo, DM; Dean, AS; Groenheit, R; Ismail, N; Meehan, CJ; Mostofa Kamal, SM; Niemann, S; Rigouts, L; Skrahina, A; Spitaleri, A; Tahseen, S; Utpatel, C; Zignol, M | 1 |
| Everitt, D; Li, M; Mendel, CM; Nedelman, JR; Salinger, DH; Spigelman, M; Subramoney, V; Wade, K; Woolson, R | 1 |
| Coutisson, S; Dalal, A; Das, M; Ferlazzo, G; Hossain, FN; Isaakidis, P; Kalon, S; Lachenal, N; Laxmeshwar, C; Mamnoon, F; Mansoor, H; Mathur, T; Meneguim, AC; Paryani, R; Ravi, S; Singh, P | 1 |
| Jeon, D; Kang, H; Kwon, YS; Shim, TS; Yim, JJ | 1 |
| Gibiansky, E; Mallikaarjun, S; Wang, X | 1 |
| Chopra, S; Dasgupta, A; Thakare, R | 1 |
| Breitscheidel, L; Ghosh, S; Hafkin, J; Hittel, N; Lazarevic, N; Martin, A | 1 |
| Al-Shaer, MH; Alghamdi, WA; Barbakadze, K; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
| Comins, K; Conradie, F; Cramer, YS; De Los Rios, J; Diacon, AH; Donahue, K; Dooley, KE; Hafner, R; Lama, JR; Maartens, G; Moran, L; Morganroth, J; Rosenkranz, SL; Shenje, J; von Groote-Bidlingmaier, F | 1 |
| Kalinin, S; Krasavin, M; Paramonova, P; Vedekhina, T | 1 |
| Acharya, S; Chavan, V; Das, M; Dhakulkar, S; Ferlazzo, G; Isaakidis, P; Iyer, A; Kalon, S; Mansoor, H; Meneguim, AC; Oswal, V; Ravi, S; Rebello, L; Shah, D; Sutar, N; Thakur, HP; Vengurlekar, D | 1 |
| Begum, A; Fatima, N; Heba, SF; Parveen, U; Rafi, R; Sultana, S | 1 |
| Bacchetti, P; Dheda, K; Esmail, A; Gandhi, M; Gerona, R; Huo, S; Metcalfe, J; Reckers, A | 1 |
| Adenov, MM; Algozhin, YZ; Berikova, EA; Issayeva, AM; Maretbayeva, SM; Rakisheva, AS; Rich, ML; Seung, KJ; Stambekova, AT; Yedilbayev, A; Yeraliyeva, LT | 1 |
| Hwang, H; Jeon, D; Kang, H; Kwon, YS; Shim, TS; Yim, JJ | 1 |
| Acquah, R; Daniels, J; Furin, J; Loveday, M; Mohr-Holland, E; Mudaly, V; Reuter, A | 1 |
| Abdel-Rahman, SM; Mirzayev, F; Stancil, SL | 1 |
| de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A | 1 |
| Gupta, R; Hafkin, J; Hittel, N; Martin, A | 2 |
| Avaliani, Z; Ferlazzo, G; Hayrapetyan, A; Hewison, C; Jonckheere, S; Khaidarkhanova, Z; Lachenal, N; Mohr, E; Sinha, A; Skrahina, A; Vambe, D; Varaine, F; Vasilyeva, I | 1 |
| Jo, KW; Nam, GB; Shim, TS; Yoon, HY | 1 |
| Kabra, SK; Lodha, R; Mukherjee, A | 1 |
| Chang, KC; Cox, H; Dheda, K; Esmail, A; Lange, C; Wasserman, S | 1 |
| Cox, V; Furin, J; Lessem, E | 1 |
| Alland, D; Bajaj, A; Dhiman, R; Gosain, TP; Hwang, YK; Jung, MG; Kidwai, S; Kumar, P; Kumar, S; Lee, IY; Mawatwal, S; Park, CY; Singh, R; Song, CS; Tiwari, P | 1 |
| Dowdy, D; Merritt, MW; Taylor, H; von Delft, A; Zwerling, A | 1 |
| Cox, H; Cox, V; Ditiu, L; Furin, J; Garcia-Prats, A; Koenig, S; Lessem, E; Nathavitharana, R; Reuter, A; Seddon, JA; Stillo, J; Tisile, P; von Delft, A; von Delft, D | 1 |
| Hwang, SH; Jeon, D; Kang, B; Kang, H; Koh, WJ; Lee, T; Mok, J; Park, JS; Yim, JJ | 1 |
| Barkane, L; Gupta, R; Hittel, N; Kuksa, L | 1 |
| Aarti, C; Barbabosa-Pliego, A; Khusro, A; Salem, AZM | 1 |
| Cox, V; Furin, J | 1 |
| Barkane, L; Caumes, E; Fréchet-Jachym, M; Guglielmetti, L; Kuksa, L; Le Dû, D; Marigot-Outtandy, D; Robert, J; Veziris, N; Yazdanpanah, Y | 1 |
| Migliori, GB; Tadolini, M; Tiberi, S | 1 |
| Cox, H; De Avezedo, V; Egazaryan, L; Ferlazzo, G; Furin, J; Hewison, C; Hughes, J; Isaakidis, P; Jonckheere, S; Kalon, S; Khachatryan, N; Laxmeshwar, C; Mohr, E; Shroufi, A | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Spanevello, A; Visca, D | 1 |
| Bujalska-Zadrozny, M; Pstragowski, M; Zbrzezna, M | 1 |
| Hun Choe, Y; Kim, CT; Kim, HR; Kim, TO; Ko, YC; Kwon, YS; Shin, HJ | 1 |
| Uplekar, M | 1 |
| Brigden, G; Cox, V; Crespo, RH; Furin, J; Lessem, E; Lynch, S; Rich, ML; Waning, B | 1 |
| Falzon, D; Halleux, CM; Jaramillo, E; Merle, C; Mirzayev, F; Olliaro, P; Weyer, K | 1 |
| Hauser, J; Jaramillo, E; Kuwana, R; Masini, T; Nhat Linh, N | 1 |
| Chang, KC; Chau, CH; Lam, FM; Law, WS; Lee, SN; Leung, CC; Leung, EC; Leung, WM; Mok, TY; Tai, LB; Yew, WW | 1 |
| Ade, S; Alikhanova, N; Benedetti, G; Cox, H; Daniels, J; De Azevedo, V; Edwards, J; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Mohr, E; Reuter, A; Shroufi, A; Steele, SJ; Trivino Duran, L | 1 |
| Bothamley, G; Burman, M; Guglielmetti, L; Kunst, H; Lange, C; Tiberi, S; Togonidze, T; Wejse, C | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Sotgiu, G; Spanevello, A; Tadolini, M; Tiberi, S; Visca, D | 1 |
| Borroni, E; Cirillo, DM; Crook, DW; Cugnata, F; Davies, TJ; Fowler, PW; Gibertoni Cruz, AL; Grazian, C; Hoosdally, SJ; Peto, TEA; Rancoita, PMV; Walker, TM | 1 |
| Choi, H; Kim, KJ; Lee, SH; Yang, JS | 1 |
| Perdigão, J; Portugal, I | 1 |
| Fan, Q; Ming, WK; Yip, WY; You, JHS | 1 |
| Li, Y; Sun, F; Zhang, W | 1 |
| Centis, R; Migliori, GB; Sotgiu, G | 1 |
| Balanag, V; Bielskiene, V; Cadena, E; Caoili, J; Cirule, A; Danilovits, M; Davidaviciene, E; Domente, L; Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Lizarbe, V; Patientia, R; Petersen, C; Sanchez, E; Segura, P; Staples, S; Ticona, E; Variava, E; von Groote-Bidlingmaier, F; Wells, C; Yu, C | 1 |
| Ahn, H; Ahn, JH; Cho, SN; Hahn, S; Jang, JY; Jeon, D; Jhun, BW; Jo, KW; Kang, YA; Kim, CK; Kim, DK; Kim, JS; Kim, SY; Kim, YR; Koh, WJ; Lee, JH; Lee, JY; Lee, M; Lee, SH; Lee, T; Mok, J; Park, JS; Shim, TS; Shin, S; Shin, SJ; Song, T; Won, HJ; Yim, JJ | 1 |
| Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS | 1 |
| Arora, VK; Chopra, KK | 1 |
| Khalid, UK; Mathuria, KK; Munjal, SK; Myneedu, VP; Puri, MM; Sarin, R; Singla, N; Singla, R; Verma, A; Vohra, V | 1 |
| Cox, H; Furin, J; Loveday, M; Reuter, A; Seddon, JA | 1 |
| Chu, N; Huang, H; Jing, W; Pang, Y; Shang, Y; Wang, F; Wen, S; Xue, Y; Zhang, T; Zong, Z | 1 |
| Akkerman, O; Al-Marzouqi, NH; Aleksa, A; Alffenaar, JW; Arias-Guillén, M; Belilovski, E; Bernal, E; Boeree, MJ; Borisov, SE; Bruchfeld, J; Cadiñanos Loidi, J; Cai, Q; Caminero, JA; Cebrian Gallardo, JJ; Centis, R; Codecasa, LR; D'Ambrosio, L; Dalcolmo, M; Danila, E; Dara, M; Davidavičienė, E; Davies Forsman, L; De Los Rios Jefe, J; Denholm, J; Duarte, R; Elamin, SE; Ferrarese, M; Filippov, A; Ganatra, S; Garcia, A; García-García, JM; Gayoso, R; Giraldo Montoya, AM; Gomez Rosso, RG; Gualano, G; Hoefsloot, W; Ilievska-Poposka, B; Jonsson, J; Khimova, E; Kuksa, L; Kunst, H; Laniado-Laborín, R; Li, Y; Magis-Escurra, C; Manfrin, V; Manga, S; Marchese, V; Martínez Robles, E; Maryandyshev, A; Matteelli, A; Migliori, GB; Mullerpattan, JB; Munoz-Torrico, M; Mustafa Hamdan, H; Nieto Marcos, M; Noordin, NM; Palmero, DJ; Palmieri, F; Payen, MC; Piubello, A; Pontali, E; Pontarelli, A; Quirós, S; Rendon, A; Skrahina, A; Šmite, A; Solovic, I; Sotgiu, G; Souleymane, MB; Spanevello, A; Stošić, M; Tadolini, M; Tiberi, S; Udwadia, ZF; van den Boom, M; Vescovo, M; Viggiani, P; Visca, D; Zhurkin, D; Zignol, M | 1 |
| De Azevedo, V; Ferlazzo, G; Hewison, C; Isaakidis, P; Mohr, E | 1 |
| Bethunaickan, R; Chandramohan, Y; Padmanaban, V; Ranganathan, UD; Swaminathan, S; Tripathy, S | 1 |
| Jeon, D; Jhun, BW; Kang, B; Kang, H; Koh, WJ; Kwak, N; Lee, T; Mok, J; Yim, JJ | 1 |
| Sharma, S | 1 |
| Karekar, SR; Marathe, PA | 1 |
| Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH | 1 |
| Caoili, JC; Chawla, P; Dartois, V; Dooley, KE; Ganatra, S; Gler, MT; Jain, SK; Peloquin, CA; Pieterse, L; Ritchie, B; Tornheim, JA; Tucker, EW; Udwadia, ZF; Zimmerman, MD | 1 |
| Schaberg, T | 1 |
| Liu, Y; Sha, W; Tang, S; Xiao, H; Zhang, Q | 1 |
| Alsultan, A; Belchis, DA; Dutta, NK; Gniadek, TJ; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML | 1 |
| Boechat, N; Branco, FS; Pinto, AC | 1 |
| Balasegaram, M; Brigden, G; du Cros, P; Horsburgh, CR; Hughes, J; McIlleron, H; Mitnick, CD; Nuermberger, E; Nyang'wa, BT; Phillips, PP; Rich, M; Varaine, F | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 2 |
| Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA | 1 |
| Lo, JH; Ryan, NJ | 1 |
| Blair, HA; Scott, LJ | 1 |
| Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
| Centis, R; D'ambrosio, L; Migliori, GB; Sotgiu, G | 1 |
| Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F | 1 |
| Gund, MG; Mangu, NK; Nair, V; Okello, MO; Seo, BI | 1 |
| Lynch, JB; Szumowski, JD | 1 |
| Geiter, LJ; Gupta, R; Hittel, N; Wells, CD | 1 |
| Abubakar, I; Brown, NM; Burman, WJ; Ellington, MJ; Feuerriegel, S; Ismail, NA; Javid, B; Köser, CU; Liddell, K; Moore, D; Niemann, S; Peacock, SJ; Török, ME | 1 |
| Chopra, S; Dasgupta, A; Soni, I; Thakare, R | 1 |
| Mayor, S | 1 |
| Migliori, GB; Sotgiu, G | 1 |
| Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F | 1 |
| Cox, H; Daniels, C; Furin, J; Lessem, E; McKenna, L; Mitnick, CD; Mosidi, T; Reed, C; Seaworth, B; Stillo, J; Tisile, P; von Delft, D | 1 |
| Diel, R; Hittel, N; Schaberg, T | 1 |
| Bloemberg, GV; Böttger, EC; Hömke, R; Keller, PM; Ritter, C; Valsesia, G | 1 |
| Bianchini, S; Blasi, F; Esposito, S | 1 |
| Caminero, JA; Scardigli, A | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB; Pontali, E; Sotgiu, G; Spanevello, A | 1 |
| Diel, R; Gibbert, J; Wirth, D; Wolfson, LJ | 1 |
| Bloemberg, GV; Borrell, S; Böttger, EC; Coscolla, M; Feldmann, J; Gagneux, S; Hömke, R; Keller, PM; Latshang, T; Ritter, C; Rothe, T; Schulthess, B; Stucki, D; Stuckia, D; Trauner, A | 1 |
| Brigden, G; du Cros, P; Wong, S | 1 |
| Bastard, M; Bonnet, M; du Cros, P; Hayrapetyan, A; Hewison, C; Khamraev, A; Khurkhumal, S; Kimenye, K; Sanchez-Padilla, E; Telnov, A; Themba, D; Varaine, F | 1 |
| Dawson, A; Silva, DS; Upshur, RE | 1 |
| Nau, JY | 1 |
| Brigden, G; Furin, J; Lessem, E; Lynch, S; Rich, M; Vaughan, L | 1 |
| Ben Amor, Y; Sullivan, T | 1 |
| Awad, M; Cabrera-Rivero, JL; Cirule, A; Danilovits, M; Gao, M; Geiter, LJ; Gentry, LM; Gupta, R; Sanchez-Garavito, E; Tupasi, T; Vargas-Vasquez, DE; Wells, CD; Xiao, H | 1 |
| Hamasako, Y; Hashizume, K; Kashiyama, E; Ohzone, Y; Sasabe, H; Shibata, M; Shimokawa, Y; Umehara, K | 1 |
| Nath, M; Tandon, R | 1 |
| Furin, J; Master, I | 1 |
| Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S; van der Laan, L | 1 |
| Byun, JH; Kang, HR; Lee, EK; Park, JA; Shin, JY | 1 |
| Baudin, E; Cellamare, M; Mitnick, CD; Trippa, L; Ventz, S | 1 |
| Wallis, RS | 1 |
| Centis, R; D'Ambrosio, L; Enwerem, M; Lingtsang, RD; Migliori, GB; Sadutshang, TD; Tadolini, M; Tiberi, S | 1 |
| Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A | 1 |
| Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ | 1 |
| Cooke, G; Fortunak, J; Gotham, D; Hill, A; Khoo, S; Nytko, FE; Pozniak, A | 1 |
| Centis, R; D'Ambrosio, L; Esposito, S; Migliori, GB; Pontali, E; Sotgiu, G; Tadolini, M; Tiberi, S | 1 |
| Sharma, DC | 1 |
| Brzezinski, A; Milstein, M; Mitnick, CD; Varaine, F | 1 |
| Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Wells, CD | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Dass, R; Hettle, R; Wirth, D | 1 |
| Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Muttil, P; Padilla, D; Sung, JC; Telko, M; Verberkmoes, JL | 1 |
| Lienhardt, C; Raviglione, MC; Vernon, A | 1 |
| Andries, K; Li, SY; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Tasneen, R; Taylor, D; Williams, KN | 1 |
| Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K | 1 |
| Awad, M; Cabrera-Rivero, JL; Chang, J; Danilovits, M; Gao, M; Geiter, LJ; Gler, MT; Koh, WJ; Kurve, A; Ogata, H; Park, SK; Sanchez-Garavito, E; Seaworth, B; Shim, TS; Skripconoka, V; Suh, GY; Suzuki, K; Tupasi, T; Vargas-Vasquez, DE; Wells, CD; Xiao, H | 1 |
| Chaisson, RE; Nuermberger, EL | 1 |
| Crunkhorn, S | 1 |
| Cirule, A; Danilovits, M; Geiter, LJ; Kummik, T; Kurve, A; Leimane, V; Levina, K; Manissero, D; Pehme, L; Skenders, G; Skripconoka, V; Tomson, T; Wells, CD | 1 |
| Centis, R; D'Ambrosio, L; Migliori, GB | 1 |
| Chai, SJ; Rao, CY; Varma, JK | 1 |
| Compton, C; Gheuens, J; Spigelman, M | 1 |
| Driscoll, DK; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Reynolds, RC; Rose, JD; Tompkins, NM | 1 |
| Zhang, Y | 1 |
44 review(s) available for azomycin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Pretomanid development and its clinical roles in treating tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Efficacy and Tolerability of Concomitant Use of Bedaquiline and Delamanid for Multidrug- and Extensively Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2023 |
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.
Topics: Adult; Diarylquinolines; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2023 |
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.
Topics: Animals; Antitubercular Agents; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant | 2020 |
Delamanid Resistance: Update and Clinical Management.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2020 |
Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
Topics: Antitubercular Agents; Child; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Female; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pregnancy; Tuberculosis, Multidrug-Resistant | 2020 |
Antimicrobial Activity of 5-membered Nitroheteroaromatic Compounds beyond Nitrofurans and Nitroimidazoles: Recent Progress.
Topics: Anti-Infective Agents; Antitubercular Agents; Humans; Nitrofurans; Nitroimidazoles; Prodrugs; Tuberculosis, Multidrug-Resistant | 2021 |
Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.
Topics: Antitubercular Agents; Child; Diarylquinolines; Drug Administration Schedule; Humans; India; Microbial Sensitivity Tests; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
Topics: Antitubercular Agents; Diarylquinolines; Health Services Accessibility; Human Rights; Humans; Injections; Nitroimidazoles; Oxazoles; Patient-Centered Care; Tuberculosis, Multidrug-Resistant | 2017 |
Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
Topics: Antitubercular Agents; Computational Biology; Diarylquinolines; Drug Design; Extensively Drug-Resistant Tuberculosis; Humans; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Peptides; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Topics: Adolescent; Antitubercular Agents; Child; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Humans; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant | 2017 |
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Genetics and roadblocks of drug resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Epistasis, Genetic; Humans; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Phylogeny; Tuberculosis, Multidrug-Resistant | 2019 |
Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Electrocardiography; Humans; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2019 |
[Tuberculosis: new treatment options and updated recommendations].
Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
An update on the chemistry and medicinal chemistry of novel antimycobacterial compounds.
Topics: Anti-HIV Agents; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Design; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2013 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Managing multidrug-resistant tuberculosis in children: review of recent developments.
Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2014 |
Delamanid: first global approval.
Topics: Antitubercular Agents; Drug Approval; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2014 |
Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Tuberculosis treatment and drug regimens.
Topics: Antitubercular Agents; China; Diarylquinolines; Humans; India; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; USSR | 2015 |
Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Interactions; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Long QT Syndrome; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Risk Assessment; Risk Factors; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Drug Interactions; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
Topics: Antitubercular Agents; Compassionate Use Trials; Diarylquinolines; Health Services Accessibility; Humans; Linezolid; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Vulnerable Populations | 2015 |
Bedaquiline and delamanid in tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Interactions; Drug Resistance, Bacterial; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
Management of drug resistantTB in patients with HIV co-infection.
Topics: Antitubercular Agents; Coinfection; Diarylquinolines; Disease Management; Extensively Drug-Resistant Tuberculosis; HIV Infections; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
Topics: Antitubercular Agents; Benzothiazoles; Cell Wall; Clinical Trials as Topic; Ethylenediamines; Mycobacterium tuberculosis; Nitroimidazoles; Quinolones; Rifamycins; Tuberculosis, Multidrug-Resistant | 2017 |
Adverse effects of oral second-line antituberculosis drugs in children.
Topics: Age Factors; Antitubercular Agents; Child; Diarylquinolines; Dose-Response Relationship, Drug; HIV Infections; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
Topics: Administration, Oral; Antitubercular Agents; Clinical Trials, Phase III as Topic; Diarylquinolines; Evidence-Based Medicine; Humans; Linezolid; Needles; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant | 2016 |
Delamanid in the treatment of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Clinical Trials, Phase III as Topic; Humans; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant | 2016 |
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Drug Industry; Drug Therapy, Combination; Female; Fluoroquinolones; Forecasting; Humans; Male; Nitroimidazoles; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2010 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
16 trial(s) available for azomycin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda | 2019 |
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design.
Topics: Adult; Antitubercular Agents; Colony-Forming Units Assay; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Nitroimidazoles; Safety; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2021 |
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Nitroimidazoles; Oxazoles; Peru; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, m
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Humans; Levofloxacin; Linezolid; Male; Middle Aged; Multicenter Studies as Topic; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Republic of Korea; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
Topics: Adolescent; Adult; Antitubercular Agents; China; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Nitroimidazoles; Oxazoles; Placebo Effect; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2013 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.
Topics: Biomarkers; Follow-Up Studies; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2015 |
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Capacity Building; Clinical Protocols; Documentation; Drug Approval; Humans; International Cooperation; Nitroimidazoles; Oxazoles; Research Design; Tuberculosis, Multidrug-Resistant | 2016 |
Delamanid for multidrug-resistant pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Sputum; Survival Analysis; Tuberculosis, Multidrug-Resistant; Young Adult | 2012 |
130 other study(ies) available for azomycin and Tuberculosis, Drug-Resistant
| Article | Year |
|---|---|
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2021 |
Novel 2-Nitroimidazole and Imidazooxazole Derivatives and their Activity against Trypanosoma cruzi and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Trypanosoma cruzi; Tuberculosis, Multidrug-Resistant | 2022 |
Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Humans; Infant; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant | 2021 |
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Topics: Antitubercular Agents; Diarylquinolines; Electrolytes; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Delamanid or pretomanid? A Solomonic judgement!
Topics: Antitubercular Agents; Diarylquinolines; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Extensively Drug-Resistant Tuberculosis; Feasibility Studies; Female; Humans; Male; Meropenem; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2022 |
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Topics: Antitubercular Agents; Clofazimine; Cohort Studies; Diarylquinolines; Electrolytes; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
Male reproductive hormones in patients treated with pretomanid.
Topics: Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Nitroimidazoles; Testosterone; Tuberculosis, Multidrug-Resistant | 2022 |
Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline.
Topics: Adult; Albumins; Antitubercular Agents; Diarylquinolines; HIV Infections; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Pretomanid in the Treatment of Patients with Tuberculosis in the United States.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant; United States | 2022 |
[Expert consensus on clinical application of delamanid].
Topics: Consensus; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Pediatric delamanid treatment for children with rifampicin-resistant TB.
Topics: Antitubercular Agents; Child; Humans; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
The
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Dynamic
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Humans; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Rabbits; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant | 2022 |
Update on drug treatments for multidrug resistant tuberculosis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2023 |
Pretomanid-resistant tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Nitroimidazoles; Oxazolidinones; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Topics: Antitubercular Agents; Diarylquinolines; Female; Humans; Middle Aged; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2023 |
The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Female; Humans; Long QT Syndrome; Male; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2023 |
The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2023 |
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Nitroimidazoles; Observational Studies as Topic; Oxazoles; Prospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
BPaL approved for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Drug Therapy, Combination; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Breakthrough in the treatment of drug-resistant tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2020 |
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2020 |
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Female; Georgia; Humans; Male; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2020 |
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria.
Topics: Antitubercular Agents; Bacteria, Anaerobic; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant | 2020 |
Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid.
Topics: Adult; Aged; Antitubercular Agents; Diarylquinolines; Female; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
Topics: Humans; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Tuberculosis, Multidrug-Resistant | 2020 |
Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Operational Research on the Treatment of Drug-Resistant Tuberculosis: Exciting Results That Need to Be Protected.
Topics: Diarylquinolines; Humans; Nitroimidazoles; Operations Research; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.
Topics: Africa; Antitubercular Agents; Asia; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; South America; Tuberculosis, Multidrug-Resistant | 2020 |
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.
Topics: Antitubercular Agents; Diarylquinolines; Genomics; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2020 |
An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant | 2020 |
One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Female; Humans; India; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2021 |
Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
Topics: Antitubercular Agents; Cohort Studies; Diarylquinolines; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant | 2021 |
Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Humans; Middle Aged; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Pretomanid for the treatment of pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2020 |
Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Compassionate Use Trials; Humans; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India.
Topics: Adolescent; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; Humans; India; Infant; Infant, Newborn; Male; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples.
Topics: Chromatography, Liquid; Hair; Humans; Limit of Detection; Linear Models; Nitroimidazoles; Oxazoles; Reproducibility of Results; Tandem Mass Spectrometry; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
Topics: Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
Topics: Antitubercular Agents; Cohort Studies; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients.
Topics: Adult; Antitubercular Agents; Child Health; Child, Preschool; Diarylquinolines; Female; Humans; Infant; Infant Health; Linezolid; Nitroimidazoles; Oxazoles; Pregnancy; Pregnancy Outcome; Pregnant Women; South Africa; Tuberculosis, Multidrug-Resistant; Young Adult | 2021 |
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Communicable Disease Control; Compassionate Use Trials; Extensively Drug-Resistant Tuberculosis; Female; Global Health; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Six-Month Response to Delamanid Treatment in MDR TB Patients.
Topics: Adolescent; Antitubercular Agents; Female; Hepatitis C; HIV Infections; Humans; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant | 2017 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2017 |
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autophagy; Cell Line, Tumor; Disease Models, Animal; Escherichia coli; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Phenanthrolines; Structure-Activity Relationship; THP-1 Cells; Tuberculosis, Multidrug-Resistant | 2017 |
Incorporating social justice and stigma in cost-effectiveness analysis: drug-resistant tuberculosis treatment.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Decision Trees; Diarylquinolines; Humans; Models, Theoretical; Nitroimidazoles; Oxazoles; Social Justice; Social Stigma; South Africa; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacteriological Techniques; Drug-Related Side Effects and Adverse Reactions; Female; Hospitals; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2018 |
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Extensively Drug-Resistant Tuberculosis; Female; Humans; Latvia; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied?
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Humans; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.
Topics: Adult; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; France; Humans; Latvia; Male; Nitroimidazoles; Oxazoles; Patient Safety; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.
Topics: Armenia; Diarylquinolines; Humans; India; Nitroimidazoles; Oxazoles; Retrospective Studies; South Africa; Tuberculosis, Multidrug-Resistant | 2018 |
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Armenia; Arrhythmias, Cardiac; Cohort Studies; Diarylquinolines; Drug Therapy, Combination; HIV Infections; Humans; India; Nitroimidazoles; Oxazoles; Retrospective Studies; South Africa; Tuberculosis, Multidrug-Resistant | 2018 |
Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Topics: Adult; Antitubercular Agents; Cohort Studies; Diarylquinolines; Drug Administration Schedule; Female; Geography; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Using new TB tools: global rhetoric and ground reality.
Topics: Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Internationality; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
Topics: Antitubercular Agents; Communicable Disease Control; Databases, Factual; Diarylquinolines; Humans; Infectious Disease Medicine; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Patient Safety; Public Health; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?
Topics: Antitubercular Agents; Diarylquinolines; Diffusion of Innovation; Drug and Narcotic Control; Drug Approval; Global Health; Health Services Accessibility; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
Topics: Adult; Antitubercular Agents; Female; Hong Kong; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2018 |
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Topics: Adult; Antitubercular Agents; Female; Humans; Logistic Models; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.
Topics: Antitubercular Agents; Cardiotoxicity; Cross-Sectional Studies; Diarylquinolines; Electrocardiography; Europe; Humans; Internationality; Long QT Syndrome; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reproducibility of Results; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2018 |
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Topics: Antitubercular Agents; Diarylquinolines; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Republic of Korea; Tuberculosis, Multidrug-Resistant | 2018 |
Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Topics: Adult; Cost-Benefit Analysis; Diarylquinolines; Follow-Up Studies; Hong Kong; Humans; Middle Aged; Monte Carlo Method; Nitroimidazoles; Oxazoles; Quality-Adjusted Life Years; Retrospective Studies; Socioeconomic Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Compassionate Use Trials; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Internationality; Male; Middle Aged; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Delamanid: does it have a role in tuberculosis treatment?
Topics: Double-Blind Method; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis.
Topics: Antitubercular Agents; Electrocardiography; Humans; Long QT Syndrome; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Journey of tuberculosis control in India.
Topics: Antitubercular Agents; Diarylquinolines; Directly Observed Therapy; Goals; History, 20th Century; History, 21st Century; Humans; India; National Health Programs; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Topics: Adult; Cardiotoxicity; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Imipenem; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Salvage Therapy; Sputum; Survival Rate; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
The STREAM trial: missed opportunities and lessons for future clinical trials.
Topics: Antitubercular Agents; Deafness; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Time Factors; Tuberculosis, Multidrug-Resistant | 2019 |
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Nitroimidazoles; Oxazoles; Pilot Projects; Tuberculosis; Tuberculosis, Multidrug-Resistant; World Health Organization | 2019 |
Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Topics: Antitubercular Agents; Cohort Studies; Diarylquinolines; Drug Therapy, Combination; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Synergism; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis, Multidrug-Resistant; Xanthenes | 2019 |
Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea.
Topics: Adult; Extensively Drug-Resistant Tuberculosis; Female; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Republic of Korea; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Undergraduate Medical Teaching: Time to integrate?
Topics: Antitubercular Agents; Drug Approval; Education, Medical; Humans; India; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2018 |
Current Status of Delamanid in the Management of MDR Tuberculosis.
Topics: Antitubercular Agents; Child; Female; Humans; India; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pregnancy; Tuberculosis, Multidrug-Resistant | 2018 |
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
Topics: Animals; Antitubercular Agents; Central Nervous System; Female; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rabbits; Treatment Outcome; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant | 2019 |
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Guinea Pigs; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Organ Size; Pyrazinamide; Recurrence; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Principles for designing future regimens for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Approval; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2014 |
A novel molecule with notable activity against multi-drug resistant tuberculosis.
Topics: Antitubercular Agents; Cytochrome P-450 Enzyme System; Drug Design; Drug Synergism; Glucuronosyltransferase; Half-Life; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Pyridones; Tuberculosis, Multidrug-Resistant | 2015 |
Drug-resistance mechanisms and tuberculosis drugs.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Humans; Mutation; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
New drug combination may shorten tuberculosis treatment, study says.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
New effective antituberculosis regimens.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
Topics: Adult; Antitubercular Agents; Cost-Benefit Analysis; Drug Costs; Female; Germany; Humans; Male; Markov Chains; Nitroimidazoles; Oxazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Reference Values; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Topics: Antitubercular Agents; Carbapenems; Clavulanic Acid; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Infectious Disease Medicine; Linezolid; Nitroimidazoles; Oxazoles; Practice Guidelines as Topic; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Germany; Humans; Markov Chains; Models, Economic; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2015 |
Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Male; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Barriers to new drug development in respiratory disease.
Topics: Antitubercular Agents; Awards and Prizes; Diarylquinolines; Drug Discovery; Extensively Drug-Resistant Tuberculosis; Humans; Motivation; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Topics: Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Eswatini; Female; Humans; Kenya; Logistic Models; Male; Middle Aged; Multivariate Analysis; Mycobacterium tuberculosis; Nitroimidazoles; Odds Ratio; Oxazoles; Patient Selection; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; USSR; Young Adult | 2016 |
Reciprocity and Ethical Tuberculosis Treatment and Control.
Topics: Antitubercular Agents; Beneficence; Communicable Disease Control; Congresses as Topic; Diarylquinolines; Directly Observed Therapy; Ethical Analysis; Ethical Theory; Global Health; Humans; Moral Obligations; Nitroimidazoles; Oxazoles; Patient Isolation; Personal Autonomy; Pharmacovigilance; Poverty; Public Health; Social Justice; Social Responsibility; Tuberculosis, Laryngeal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Virtues | 2016 |
[New antitubercular agents are not where where we need them to be].
Topics: Antitubercular Agents; Developing Countries; Diarylquinolines; Health Services Accessibility; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2015 |
Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
Topics: Antitubercular Agents; Diarylquinolines; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Humans; Legislation, Drug; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.
Topics: Animals; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Cell Line; Drug Interactions; HEK293 Cells; Humans; Kidney Tubules, Proximal; Neoplasm Proteins; Nitroimidazoles; Octamer Transcription Factor-1; Organic Anion Transporters; Oxazoles; Solute Carrier Proteins; Swine; Tuberculosis, Multidrug-Resistant | 2016 |
Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
Topics: Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Health Services Accessibility; Humans; Male; Nitroimidazoles; Oxazoles; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2016 |
Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
Topics: Aged; Diarylquinolines; Female; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Quality-Adjusted Life Years; Tuberculosis, Multidrug-Resistant | 2016 |
A Bayesian response-adaptive trial in tuberculosis: The endTB trial.
Topics: Adaptive Clinical Trials as Topic; Algorithms; Antitubercular Agents; Bayes Theorem; Computer Simulation; Diarylquinolines; Humans; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2016 |
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis.
Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2017 |
Estimated generic prices for novel treatments for drug-resistant tuberculosis.
Topics: Algorithms; Antitubercular Agents; Commerce; Diarylquinolines; Drug Costs; Drugs, Generic; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2017 |
India plans to expand access to new tuberculosis drug.
Topics: Antitubercular Agents; Diarylquinolines; Health Services Accessibility; Humans; India; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Topics: Adult; Antitubercular Agents; Clinical Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Drug Therapy, Combination; Female; Germany; Humans; Linezolid; Male; Nitroimidazoles; Observational Studies as Topic; Oxazoles; Quality-Adjusted Life Years; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Colony Count, Microbial; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Guinea Pigs; Humans; Latent Tuberculosis; Lung; Male; Nitroimidazoles; Particle Size; Powders; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2010 |
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Secondary Prevention; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2011 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2012 |
Confronting multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Epidemics; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2012 |
Trial watch: Novel antimicrobial fights TB resistance.
Topics: Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Design; Humans; Medication Adherence; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2012 |
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitroimidazoles; Oxazoles; Randomized Controlled Trials as Topic; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2013 |
Multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Epidemics; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2012 |
Multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Epidemics; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2012 |
Multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Epidemics; Female; Humans; Male; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2012 |
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Specific Pathogen-Free Organisms; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |